RESULTS OF MULTIDRUG-RESISTANT TUBERCULOSIS TREATMENT USING NEW DRUGS AND CELLULAR TECHNOLOGIES

The detection of multidrug-resistant and extensively drug-resistant tuberculosis cases has become a major public health problem and an obstacle to effective global tuberculosis control.

We have set the task to improve the effectiveness of treatment of patients with multidrug-resistant and extensively drugresistant tuberculosis using new drugs and developed chemotherapy regimens, as well as cellular technologies as a method of additive therapy. Based on the cohort analysis, the effectiveness of treatment was assessed using new and re-profiled antituberculosis drugs, including Bedaquiline and Delamanid. A method of autologous transplantation of multipotent mesenchymal stromal cells was developed, which was included into the complex therapy of patients. Preliminary results of the conducted studies testify to the high effectiveness of new antituberculosis treatment regimens. Autologous transplantation of multipotent mesenchymal stromal cells against the background of individualized chemotherapy speeds up the conversion of sputum and ultimately significantly improves the final results of treatment of patient. Despite the fact that cellular technologies in the treatment of tuberculosis are not widely used at present, these methods aimed at eliminating the causative agent of tuberculosis and the regeneration of damaged lung tissue will be in great demand in the future, primarily because of the significant advantage compared with the use of antituberculosis drugs means – the absence of development of resistance of mycobacteria tuberculosis. 

1. Global tuberculosis report 2016. Geneva, World Health Organization Publ., 2016. 214 p.

2. Gurevich G. L., Kalechits O. M. Tuberculosis: pathogen, pathogenesis, risk of disease, epidemiology. Mir meditsiny [World of Medicine], 2012, no. 5, pp. 3–4 (in Russian).

3. World Health Organization, the HWO/IUATLD Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis Drug Resistance in the World: Forth Global Report. WHO/HTM/TB/2008.394. Geneva, World Health Organization Publ., 2008. 64 p.

4. Skryagina E. M., Astrovko A. P., Gurevich G. L., Dyus’mikeeva M. I., Skryagin A. E., Zalutskaya O. M., Solodovnikova V. V. The effect of multiple drug resistance on the effectiveness of treatment of patients with tuberculosis. Retsept = Recipe, 2010, no. 1, pp. 61–66 (in Russian).

5. Skrahina A., Hurevich H., Zalutskaya A., Sahalchyk E., Astrauko A., Hoffner S., Rusovich V., Dadu A., de Colombani P., Dara M., van Gemert W., Zignol M. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bulletin of the World Health Organization, 2013, vol. 91, no. 1, pp. 36–45. DOI: 10.2471/blt.12.104588

6. Falzon D., Gandhi N., Migliori G. B., Sotgiu G., Cox H., Holtz T. H., Hollm-Delgado M. G., Keshavjee S., DeRiemer K., Centis R., D’Ambrosio L., Lange C. G., Bauer M., Menzies D. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. European Respiratory Journal, 2013, vol. 42, no. 1, pp. 156–168. DOI: 10.1183/09031936.00134712

7. Migliori G. B., Sotgiu G., Gandhi N. R., Falzon D., DeRiemer K., Centis R., Hollm-Delgado M. G., Palmero D., Pérez-Guzmán C., Vargas M. H., D’Ambrosio L., Spanevello A., Bauer M., Chan E. D., Schaaf H. S., Keshavjee S., Holtz T. H., Menzies D. Drug resistance beyond extensively drug resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2013, vol. 42, no. 1, pp. 169–179. DOI: 10.1183/09031936.00136312

8. Migliori G. B., Espinal M., Danilova I. D., Punga V. V., Grzemska M., Raviglione M. C. Frequency of recurrence among MDR-TB cases «successfully» treated with standardised short-course chemotherapy. International Journal of Tuberculosis and Lung Disease, 2002, vol. 6, no. 10, pp. 858–864.

9. Diel R., Vandeputte J., de Vries G., Stillo J., Wanlin M., Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. European Respiratory Journal, 2014, vol. 43, no. 2, pp. 554–565. DOI: 10.1183/09031936.00079413

10. Caminero J. A., Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence. European Respiratory Journal, 2015, vol. 46, no. 4, pp. 887–893. DOI: 10.1183/13993003.00432-2015

11. Sotgiu G., Pontali E., Migliori G. B. Linezolid to treat MDR-/XDR-Tuberculosis: available evidence and future scenarios. European Respiratory Journal, 2015, vol. 45, no. 1, pp. 25–29. DOI: 10.1183/09031936.00145014

12. Diel R., Rutz S., Castell S., Schaberg T. Tuberculosis: cost of illness in Germany. European Respiratory Journal, 2012, vol. 40, no. 1, pp. 143–150. DOI: 10.1183/09031936.00204611

13. Migliori G. B., de Iaco G., Besozzi G., Centis R., Cirillo D. M. First tuberculosis cases in Italy resistant to all tested drugs. Eurosurveillance (Weekly releases), 2007, vol. 12, no. 5, E070517.1.

14. Pontali E., Sotgiu G., D’Ambrosio L., Centis R., Migliori G. B. Bedaquiline and MDR-TB: a systematic and critical analysis of the evidence. European Respiratory Journal, 2016, vol. 47, no. 2, pp. 394–402. DOI: 10.1183/13993003.01891-2015

15. Falzon D., Jaramillo E., Schünemann H. J., Arentz M., Bauer M., Bayona J., Blanc L., Caminero J. A., Daley C. L., Duncombe C., Fitzpatrick C., Gebhard A., Getahun H., Henkens M., Holtz T. H., Keravec J., Keshavjee S., Khan A. J., Kulier R., Leimane V., Lienhardt C., Lu C., Mariandyshev A., Migliori G. B., Mirzayev F., Mitnick C. D., Nunn P., Nwagboniwe G., Oxlade O., Palmero D., Pavlinac P., Quelapio M. I., Raviglione M. C., Rich M. L., Royce S., Rüsch-Gerdes S., Salakaia A., Sarin R., Sculier D., Varaine F., Vitoria M., Walson J. L., Wares F., Weyer K., White R. A., Zignol M. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. European Respiratory Journal, 2011, vol. 38, no. 3, pp. 516–528. DOI: 10.1183/09031936.00073611

16. Caminero J. A., Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence. European Respiratory Journal, 2015, vol. 46, no. 4, pp. 887–893. DOI: 10.1183/13993003.00432-2015

17. Pym A. S., Diacon A. H., Tang Sh.-J., Conradie F., Danilovits M., Chuchottaworn C., Vasilyeva I., Andries K., Bakare N., de Marez T., Haxaire-Theeuwes M., Lounis N., Meyvisch P., van Baelen B., van Heeswijk R. P. G., Dannemann B. Bedaquiline in the treatment of multi- and extensively drug-resistant tuberculosis. European Respiratory Journal, 2016, vol. 47, no. 2, pp. 564–574. DOI: 10.1183/13993003.00724-2015

18. Diacon A. H., Pym A., Grobusch M., Patientia R., Rustomjee R., Page-Shipp L., Pistorius C., Krause R., Bogoshi M., Churchyard G., Venter A., Allen J., Palomino J. C., De Marez T., van Heeswijk R. P., Lounis N., Meyvisch P., Verbeeck J., Parys W., de Beule K., Andries K., Mc Neeley D. F. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. New England Journal of Medicine, 2009, vol. 360, no. 23, pp. 2397–2405. DOI: 10.1056/NEJMoa0808427.

19. Diacon A. H., Pym A., Grobusch M. P., de los Rios J. M., Gotuzzo E., Vasilyeva I., Leimane V., Andries K., Bakare N., De Marez T., Haxaire-Theeuwes M., Lounis N., Meyvisch P., De Paepe E., van Heeswijk R. P., Dannemann B. Multidrugresistant tuberculosis and culture conversion with bedaquiline. New England Journal of Medicine, 2014, vol. 371, no. 8, pp. 723–732. DOI: 10.1056/NEJMoa1313865

20. Guglielmetti L., Le Dû D., Jachym M., Henry B., Martin D., Caumes E., Veziris N., Métivier N., Robert J. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clinical Infectious Diseases, 2015, vol. 60, no. 2, pp. 188–194. DOI: 10.1093/cid/ciu786

21. Ndjeka N., Conradie F., Schnippel K., Hughes J., Bantubani N., Ferreira H., Maartens G., Mametja D., Meintjes G., Padanilam X., Variava E., Pym A., Pillay Y. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. International Journal of Tuberculosis and Lung Disease, 2015, vol. 19, no. 8, pp. 979–985. DOI: 10.5588/ijtld.14.0944

22. Tiberi S., de Lorenzo S., Centis R., Viggiani P., D’Ambrosio L., Migliori G. B. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. European Respiratory Journal, 2014, vol. 43, no. 1, pp. 289–292. DOI: 10.1183/09031936.00122313

23. Tadolini M., Lingtsang R. D., Tiberi S., Enwerem M., D’Ambrosio L., Sadutshang T. D., Centis R., Migliori G. B. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. European Respiratory Journal, 2016, vol. 48, no. 3, pp. 935–938. DOI: 10.1183/13993003.00637-2016

24. Wallis R. S. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. European Respiratory Journal, 2016, vol. 48, no. 5, pp. 1526–1527. DOI: 10.1183/13993003.01207-2016

25. Tadolini M., Lingtsang R. D., Tiberi S., Enwerem M., D’Ambrosio L., Sadutshang T. D., Centis R., Migliori G. B. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. European Respiratory Journal, 2016, vol. 48, no. 5, pp. 1527–1529. DOI: 10.1183/13993003.01552-2016

26. Meisel R., Brockers S., Heseler K., Degistirici O., Bülle H., Woite C., Stuhlsatz S., Schwippert W., Jäger M., Sorg R., Henschler R., Seissler J., Dilloo D., Däubener W. Human but not murine multipotent mesenchymal stromal cells exhibit broadspectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia, 2011, vol. 25, no. 4, pp. 648–654. DOI: 10.1038/leu.2010.310

27. Van Linthout S., Savvatis K., Miteva K., Peng J., Ringe J., Warstat K., Schmidt-Lucke C., Sittinger M., Schultheiss H. P., Tschöpe C. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis. European Heart Journal, 2010, vol. 32, no. 17, pp. 2168–2178. DOI: 10.1093/eurheartj/ehq467

28. Mei Sh. H. J., Haitsma J. J., Dos Santos C. C., Deng Y., Lai P. F. H., Slutsky A. S., Liles W. C., Stewart D. J. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. American Journal of Respiratory and Critical Care Medicine, 2010, vol. 182, no. 8, pp. 1047–1057. DOI: 10.1164/rccm.201001-0010OC

29. Krasnodembskaya A., Song Y., Fang X., Gupta N., Serikov V., Lee J.-W., Matthay M. A. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells, 2010, vol. 28, no. 12, pp. 2229–2238. DOI: 10.1002/stem.544

30. Schrepfer S., Deuse T., Reichenspurner H., Fischbein M. P., Robbins R. C., Pelletier M. P. Stem cell transplantation: the lung barrier. Transplantation Proceedings, 2007, vol. 39, no. 2, pp. 573–576. DOI: http://dx.doi.org/10.1016/j. transproceed.2006.12.019

31. Sackstein R., Merzaban J. S., Cain D. W., Dagia N. M., Spencer J. A., Lin Ch. P., Wohlgemuth R. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nature Medicine, 2008, vol. 14, no. 2, pp. 181–187. DOI: 10.1038/nm1703

32. Gao J., Dennis J. E., Muzic R. F., Lundberg M., Caplan A. I. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs, 2001, vol. 169, no. 1, pp. 12–20. DOI: 10.1159/000047856

33. Barbash I. M., Chouraqui P., Baron J., Feinberg M. S., Etzion Sh., Tessone A., Miller L., Guetta E., Zipori D., Kedes L. H., Kloner R. A., Leor J. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation, 2003, vol. 108, no. 7, pp. 863–868. DOI: 10.1161/01. CIR.0000084828.50310.6A

34. Lee R. H., Pulin A. A., Seo M. J., Kota D. J., Ylostalo J., Larson B. L., Semprun-Prieto L., Delafontaine P., Prockop D. J. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the antiinflammatory protein TSG-6. Cell Stem Cell, 2009, vol. 5, no. 1, pp. 54–63. DOI: 10.1016/j.stem.2009.05.003

35. Matthay M. A., Thompson B. T., Read E. J., McKenna D. H., Liu K. D., Calfee C. S., Lee J. W. Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest, 2010, vol. 138, no. 4, pp. 965–972. DOI: 10.1378/chest.10-0518

36. Gupta N., Su X., Popov B., Lee J. W., Serikov V., Matthay M. A. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. Journal of Immunology, 2007, vol. 179, no. 3, pp. 1855–1863. DOI: 10.4049/jimmunol.179.3.1855

37. Zhao F., Zhang Y. F., Liu Y. G., Zhou J. J., Li Z. K., Wu C. G., Qi H. W. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplantation Proceedings, 2008, vol. 40, no. 5, pp. 1700–1705. DOI: 10.1016/j.transproceed.2008.01.080

38. Ortiz L. A., Gambelli F., McBride C., Gaupp D., Baddoo M., Kaminski N., Phinney D. G. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proceedings of the National Academy of Sciences, 2003, vol. 100, no. 14, pp. 8407–8411. DOI: 10.1073/pnas.1432929100